BioArctic is a Swedish research intensive biopharma company aimed at developing new treatments that address the causes of diseases that affect the central nervous system such as Alzheimer’s and Parkinson’s. BioArctic collaborates with research groups at universities including Uppsala University and with global research and development partners including Eisai and Abbvie. CEO, Gunilla Osswald says, “We are pleased to partner with Dementia Forum X in the important work of participating in the dialogue and bringing our perspective and capabilities as a research-based biopharma company focused on neurodegenerative diseases.”
Under the patronage of HM Queen Silvia of Sweden, the Dementia Forum X gathers key stakeholders from different fields. The first Dementia Forum X was held in 2015 and the second one was held in 2017. The key themes of this year’s discussions are financing, innovation, and women’s brain health. BioArctic joins other DFX partners – AARP, Alzheimer Fonden, Alzheimer’s Disease International, Arjo, Biogen, Boklok, Dr. Ake Olsson Foundation, Global Alliance on Women’s Brain health, Home Instead Senior Care, Otsuka, Roche, Skandia, and Ohman – to connect stakeholders throughout society and undertake the future global demographic challenges.